嵌合抗原受体 T 细胞免疫疗法治疗 B 细胞非霍奇金淋巴瘤的疗效和安全性：系统评价和荟萃分析。
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
机构信息
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
出版信息
Immunotherapy. 2021 Mar;13(4):345-357. doi: 10.2217/imt-2020-0221. Epub 2021 Jan 7.
The aim was to evaluate the efficacy and safety of chimeric antigen receptor T (CAR-T) cell in B-cell non-Hodgkin lymphoma (B-NHL). A meta-analysis was conducted using eligible clinical trials, which were obtained from electronic medical literature databases. A total of 24 clinical trials with 590 patients were included. The best overall response rate was 66% and complete remission rate was 46%. The incidence rates of cytokine-release syndrome and neurotoxicity (grade ≥ 3) were 9 and 5%, respectively. The various clinical factors were analyzed. Autogenic CAR-T cell may lead to improved efficacy than allogeneic CAR-T cell. CD20 CAR-T cell may show increased efficacy than CD19 CAR-T cell. CAR-T immunotherapy has remarkable efficacy and low toxicity in relapsed/refractory B-NHL.
目的在于评估嵌合抗原受体 T （CAR-T）细胞在 B 细胞非霍奇金淋巴瘤（B-NHL）中的疗效和安全性。使用电子医学文献数据库获得了符合条件的临床试验，并进行了荟萃分析。共有 24 项临床试验，共纳入 590 名患者。最佳总体缓解率为 66%，完全缓解率为 46%。细胞因子释放综合征和神经毒性（≥3 级）的发生率分别为 9%和 5%。分析了各种临床因素。自体 CAR-T 细胞可能比同种异体 CAR-T 细胞疗效更好。CD20 CAR-T 细胞可能比 CD19 CAR-T 细胞疗效更好。CAR-T 免疫疗法在复发/难治性 B-NHL 中具有显著疗效且毒性低。
Zotero 插件